Home » Allphase Pharma Consulting » Page 32

Tag Archives: Allphase Pharma Consulting

Ibuprofen for uUTI (Part 2): Antibiotic or NSAID? Or Both? Or Neither?

Posted on by — No Comments ↓

While the news is abuzz with reports of Zika virus coming to a place near you, an interesting article on a much more mundane topic – the treatment of uncomplicated UTIs – should be competing for your attention. It is a publication we have been waiting for, as mentioned in an earlier blog. Results Continue reading Ibuprofen for uUTI (Part 2): Antibiotic or NSAID? Or Both? Or Neither?→

New Treatment Guidelines for Candidiasis – A Major Document to Study

Posted on by — No Comments ↓

In a much-quoted analysis, Lee found that most IDSA Guidelines were supported only by Level III quality data, the lowest category of evidence-based support[1]. The article concludes that more well-designed trials were needed, and clinical judgement should ultimately guide patient management. This all sounds fine and good, and the new Continue reading New Treatment Guidelines for Candidiasis – A Major Document to Study→

QIDP Antibiotics – 2015 Year-End Update

Posted on by — No Comments ↓

Here an updated listing of all QIDP drugs we are aware of as of 12/24/2015. Today just facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are 58 drugs which garnered QIDP status and these are listed in the Main Table below. With the recent Continue reading QIDP Antibiotics – 2015 Year-End Update→